≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Other congenital malformations of brain

DOID Endpoint Browser PheWeb

Q17_OTHER_CONGEN_MALFO_BRAIN

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q04
  • Cause of death: ICD-10 — Q04

2 out of 7 registries used, show all original rules.

195

4. Check minimum number of events

None

195

5. Include endpoints

None

195

6. Filter based on genotype QC (FinnGen only)

185

Control definitions (FinnGen only)

Control exclude
Q17_CONGEN_MALFO_NERVOUS_SYSTEM

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Q0
Name in latin
Aliae malformationes congenitae encephali

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2987 1324 1657
Only index persons 2131 981 1150
Unadjusted period prevalence (%)
Whole population 0.04 0.04 0.05
Only index persons 0.04 0.04 0.04
Median age at first event (years)
Whole population 5.21 6.59 3.95
Only index persons 9.59 12.95 6.73

-FinnGen-

Key figures

All Female Male
Number of individuals 185 102 83
Unadjusted period prevalence (%) 0.04 0.04 0.04
Median age at first event (years) 30.81 32.54 28.68

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
195
Matched controls
1950
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q04.8
ICD-10 Finland
Other specified congenital malformations of brain
+∞
99.8
87
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
23.4
97.5
84
61
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
34.6
84.1
57
23
N03AX14
ATC
levetiracetam; systemic
31.5
78.7
55
24
N03AF02
ATC
oxcarbazepine; oral
24.2
77.1
61
36
G40.9
ICD-10 Finland
Epilepsy, unspecified
24.1
67.0
52
29
Q04.6
ICD-10 Finland
Congenital cerebral cysts
+∞
59.5
54
*
N03AG01
ATC
valproic acid; systemic, rectal
10.9
40.5
50
60
N05CD08
ATC
midazolam; nasal, systemic
15.7
35.7
33
25
N03AX11
ATC
topiramate; oral
13.5
32.7
33
29
183
Kela drug reimbursment
Lamotrigin and topiramate
41.5
32.4
40
12
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
7.1
30.6
56
105
N05BA09
ATC
clobazam; oral
34.4
30.3
39
14
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
34.4
30.3
39
14
N03AX09
ATC
lamotrigine; oral
9.8
28.3
36
44
XA800
NOMESCO Finland
Neuropsychological investigation
7.4
27.5
46
78
G93.0
ICD-10 Finland
Cerebral cysts
155.7
26.3
27
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
7.6
25.6
41
66
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
32.7
25.5
33
12
N03AX18
ATC
lacosamide; systemic
62.2
23.7
27
5
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.8
23.4
29
34
N05BA01
ATC
diazepam; systemic, rectal
5.6
21.5
48
107
Q04.9
ICD-10 Finland
Congenital malformation of brain, unspecified
+∞
20.1
19
*
Q04.3
ICD-10 Finland
Other reduction deformities of brain
+∞
20.1
19
*
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
25.8
19.7
27
12
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
51.8
19.7
23
5
AA1AD
NOMESCO Finland
CT of head and brain
4.1
18.7
68
223
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.2
18.6
45
107
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
5.3
16.4
37
82
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
15.7
15.5
25
18
N03AX22
ATC
perampanel; oral
49.3
15.3
18
*
Q04.00
ICD-10 Finland
Agenesis of corpus callosum
+∞
14.8
14
*
AAJ20
NOMESCO Finland
Excision of epileptic focus
+∞
14.8
14
*
N88
ICPC
Epilepsy
29.8
14.6
19
7
N03AX23
ATC
brivaracetam; systemic
46.3
14.4
17
*
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
32.8
14.2
18
6
G40.10
ICD-10 Finland
Simple partial seizures
81.0
13.8
15
*
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
28.1
13.6
18
7
G40
ICD-10 Finland
Epilepsy
23.2
13.6
19
9
N03AX15
ATC
zonisamide; oral
43.4
13.4
16
*
R62.0
ICD-10 Finland
Delayed milestone
5.9
12.6
24
45
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
24.7
11.8
16
7
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.4
11.8
33
87
G40.09
ICD-10 Finland
Other or unspecified partial (focal) idiopathic epilepsy or epileptic syndrome with local onset
127.2
11.6
12
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.6
10.6
41
136
F83
ICD-10 Finland
Mixed specific developmental disorders
8.3
10.5
23
31
Z2446
NOMESCO Finland
Social worker
3.4
10.2
42
145
Z2445
NOMESCO Finland
Psychologist
3.9
10.1
33
97
N03AG04
ATC
vigabatrin; oral
27.7
9.9
13
5
181
Kela drug reimbursment
Retigabine and vigabatrin
58.0
9.7
11
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.6
9.6
35
111
Q04.08
ICD-10 Finland
Congenital malformations of corpus callosum
+∞
9.4
9
*
3069, ,
Kela drug reimbursment
+∞
9.4
9
*
1541, ,
Kela drug reimbursment
+∞
9.4
9
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.1
9.4
45
170
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
9.2
79
405
ADB00
NOMESCO Finland
Implantation of vagus nerve stimulating device
38.6
9.1
11
*
H47.2
ICD-10 Finland
Optic atrophy
38.6
9.1
11
*
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
7.8
9.0
20
28
G40.21
ICD-10 Finland
Partial epileptic seizure with cloudiness and automatism
52.4
8.8
10
*
G91.1
ICD-10 Finland
Obstructive hydrocephalus
52.4
8.8
10
*
G40.00
ICD-10 Finland
Benign childhood epilepsy with centrotemporal EEG spikes
52.4
8.8
10
*
R1260
NOMESCO Finland
Evaluation of communicative skills
12.4
8.7
15
13
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.4
8.7
35
118
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
17.3
8.7
13
8
F82
ICD-10 Finland
Specific developmental disorder of motor function
8.5
8.6
18
23
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
94.0
8.5
9
*
N03AF01
ATC
carbamazepine; oral, rectal
7.1
8.4
20
31
N03AF03
ATC
rufinamide; oral
+∞
8.4
8
*
N03AX25
ATC
cenobamate; oral
+∞
8.4
8
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.6
8.3
61
288
NE1AA
NOMESCO Finland
Pelvis X-ray examination
4.5
7.9
20
48
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.7
7.8
51
227
P85
ICPC
Mental retardation
10.7
7.7
14
14
ZXE20
NOMESCO Finland
More than three and less than five hours
3.0
7.5
38
147
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
14.1
7.5
12
9
3454A
ICD-9 Finland
Epilepsy, Partial epilepsy, with impairment of consciousness[EPILEPSIA GENERALISATA SECUNDARIA]
83.1
7.5
8
*
Z31.5
ICD-10 Finland
Genetic counselling
3.4
7.4
28
91
A28
ICPC
Limited function/disability NOS
3.1
7.3
33
119
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
+∞
7.3
7
*
N03AF04
ATC
eslicarbazepine; oral
+∞
7.3
7
*
G40.89
ICD-10 Finland
Other epilepsy
31.3
7.2
9
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.7
7.2
43
182
ZXD10
NOMESCO Finland
Scheduled procedure
2.3
7.0
80
456
H53.4
ICD-10 Finland
Visual field defects
14.5
7.0
11
8
G40.11
ICD-10 Finland
Simple partial epileptic seizure that develops into a complex partial seizure
17.5
6.8
10
6
G40.2
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
17.5
6.8
10
6
G80.2
ICD-10 Finland
Spastic hemiplegic cerebral palsy
41.5
6.8
8
*
Z3226
NOMESCO Finland
Physiotherapist
2.5
6.8
54
263
F71.0
ICD-10 Finland
Moderate mental retardation, with the statement of no, or minimal, impairment of behaviour
23.5
6.7
9
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
6.7
52
250
RS222, ,
NOMESCO Finland
10.6
6.6
12
12
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
6.6
64
339
N03AB02
ATC
phenytoin; systemic
15.0
6.5
10
7
G91.9
ICD-10 Finland
Hydrocephalus, unspecified
72.1
6.5
7
*
XF400
NOMESCO Finland
ECG with 12 standard connections
2.7
6.4
40
172
R4120
NOMESCO Finland
Occupational therapy
3.5
6.4
23
72
AAF40
NOMESCO Finland
Shunt of cyst of brain to peritoneum
+∞
6.3
6
*
Q04.4
ICD-10 Finland
Septo-optic dysplasia
+∞
6.3
6
*
199
Kela drug reimbursment
Rufinamide
+∞
6.3
6
*
R4110
NOMESCO Finland
Physiotherapy
2.2
6.2
66
362
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.6
6.2
21
63
H50.0
ICD-10 Finland
Convergent concomitant strabismus
10.5
6.1
11
11
Z3231
NOMESCO Finland
Registered nurse
2.2
6.1
70
396
ZXD05
NOMESCO Finland
Urgent procedure
2.2
6.0
63
343

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
1.8e+00
2.9e+00
3.3e+00
—
3.5e+00
2.7e+00
2.0e+00
cases:29.73%
controls:6.81%
cases:38.67%
controls:3.29%
cases:12.67%
controls:0.54%
—
—
cases:16.22%
controls:0.60%
cases:40.54%
controls:4.56%
cases:39.53%
controls:8.21%
44
100
104
1369
58
49
92
1440
19
8
131
1481
—
24
9
124
1480
60
67
88
1403
51
103
78
1151
Paediatric neurology
421 [44777781]
1.6e+00
1.7e+00
2.6e+00
1.0e+50
—
3.2e+00
2.1e+00
cases:11.49%
controls:2.45%
cases:8.67%
controls:1.75%
cases:5.33%
controls:0.40%
cases:8.00%
controls:0.00%
—
—
cases:10.14%
controls:0.48%
cases:10.85%
controls:1.44%
17
36
131
1433
13
26
137
1463
8
6
142
1483
12
0
138
1489
—
15
7
133
1463
14
18
115
1236
Neurosurgery
14 [38004459]
1.8e+00
2.4e+00
—
1.0e+50
—
3.9e+00
2.9e+00
cases:10.14%
controls:1.91%
cases:6.67%
controls:0.67%
—
—
cases:24.67%
controls:0.00%
—
—
cases:14.86%
controls:0.34%
cases:17.83%
controls:1.20%
15
28
133
1441
10
10
140
1479
—
37
0
113
1489
—
22
5
126
1465
23
15
106
1239
Outpatient Visit
OP [9202]
2.2e-01
8.6e-01
9.4e-01
5.0e+00
1.2e+00
1.3e+00
8.8e-01
cases:70.95%
controls:66.24%
cases:65.33%
controls:44.39%
cases:22.67%
controls:10.28%
cases:54.67%
controls:0.81%
cases:27.03%
controls:9.81%
cases:72.30%
controls:42.45%
cases:84.50%
controls:69.30%
105
973
43
496
98
661
52
828
34
153
116
1336
82
12
68
1477
40
146
108
1343
107
624
41
846
109
869
20
385
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
3.6e+00
3.2e+00
—
—
—
3.2e+00
—
cases:10.81%
controls:0.34%
cases:9.33%
controls:0.40%
—
—
—
—
—
—
cases:8.78%
controls:0.41%
—
—
16
5
132
1464
14
6
136
1483
—
—
—
13
6
135
1464
—
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
2.0e+00
2.1e+00
—
—
—
2.5e+00
2.5e+00
cases:8.78%
controls:1.29%
cases:5.33%
controls:0.67%
—
—
—
—
—
—
cases:8.11%
controls:0.75%
cases:6.98%
controls:0.64%
13
19
135
1450
8
10
142
1479
—
—
—
12
11
136
1459
9
8
120
1246
Supplier / Service Provider
OMOP5117446 [33004]
-7.7e-01
—
—
—
—
2.5e+00
2.8e+00
cases:13.51%
controls:25.32%
—
—
—
—
—
—
—
—
cases:4.05%
controls:0.34%
cases:8.53%
controls:0.56%
20
372
128
1097
—
—
—
—
6
5
142
1465
11
7
118
1247
Psychiatry
26 [38004469]
8.4e-01
1.0e+00
7.4e-01
—
9.2e-01
1.0e+00
1.4e+00
cases:15.54%
controls:7.35%
cases:11.33%
controls:4.37%
cases:3.33%
controls:1.61%
—
—
cases:5.41%
controls:2.22%
cases:11.49%
controls:4.49%
cases:23.26%
controls:6.70%
23
108
125
1361
17
65
133
1424
5
24
145
1465
—
8
33
140
1456
17
66
131
1404
30
84
99
1170
Headache
R51.80 [2000503603]
1.2e+00
2.3e+00
—
—
—
1.5e+00
1.5e+00
cases:5.41%
controls:1.63%
cases:6.00%
controls:0.60%
—
—
—
—
—
—
cases:3.38%
controls:0.75%
cases:10.08%
controls:2.55%
8
24
140
1445
9
9
141
1480
—
—
—
5
11
143
1459
13
32
116
1222
oxcarbazepine; oral
N03AF02 [21604418]
3.7e+00
—
—
—
—
—
—
cases:16.89%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
25
7
123
1462
—
—
—
—
—
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.4e+00
1.4e+00
—
—
-1.0e+50
1.3e+00
2.3e+00
cases:6.76%
controls:1.77%
cases:4.00%
controls:1.01%
—
—
—
—
cases:0.00%
controls:0.34%
cases:3.38%
controls:0.95%
cases:11.63%
controls:1.36%
10
26
138
1443
6
15
144
1474
—
—
0
5
148
1484
5
14
143
1456
15
17
114
1237
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
8.6e-01
1.8e+00
—
—
—
—
1.7e+00
cases:6.08%
controls:2.65%
cases:4.67%
controls:0.81%
—
—
—
—
—
—
—
—
cases:8.53%
controls:1.59%
9
39
139
1430
7
12
143
1477
—
—
—
—
11
20
118
1234
Case Management Agency
251B00000X [38004193]
6.0e-02
2.3e-01
4.6e-01
3.4e+00
3.1e-01
2.8e-01
3.7e-01
cases:54.73%
controls:53.23%
cases:53.33%
controls:47.62%
cases:29.33%
controls:20.75%
cases:25.33%
controls:1.07%
cases:25.00%
controls:19.61%
cases:59.46%
controls:52.65%
cases:76.74%
controls:69.54%
81
782
67
687
80
709
70
780
44
309
106
1180
38
16
112
1473
37
292
111
1197
88
774
60
696
99
872
30
382
Outpatient Hospital
22 [8756]
3.1e-01
1.1e+00
—
1.0e+50
1.2e+00
1.5e+00
7.8e-01
cases:27.03%
controls:21.38%
cases:14.67%
controls:5.57%
—
—
cases:7.33%
controls:0.00%
cases:3.38%
controls:1.01%
cases:17.57%
controls:4.69%
cases:31.78%
controls:17.54%
40
314
108
1155
22
83
128
1406
—
11
0
139
1489
5
15
143
1474
26
69
122
1401
41
220
88
1034
Pharmacy visit
OMOP4822462 [581458]
1.7e-02
7.9e-01
6.6e-01
1.8e+00
8.2e-01
7.4e-01
7.0e-01
cases:91.89%
controls:91.76%
cases:88.00%
controls:76.83%
cases:50.67%
controls:34.79%
cases:9.33%
controls:1.75%
cases:54.73%
controls:34.65%
cases:88.51%
controls:78.57%
cases:96.90%
controls:93.94%
136
1348
12
121
132
1144
18
345
76
518
74
971
14
26
136
1463
81
516
67
973
131
1155
17
315
125
1178
4
76
Epilepsy, unspecified
G40.9 [45562083]
3.0e+00
—
—
—
—
—
—
cases:7.43%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
11
6
137
1463
—
—
—
—
—
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.5e-01
7.7e-01
1.5e+00
—
1.1e+00
5.6e-01
6.3e-01
cases:27.03%
controls:22.46%
cases:24.00%
controls:12.76%
cases:10.00%
controls:2.35%
—
—
cases:6.08%
controls:2.15%
cases:22.97%
controls:14.56%
cases:44.19%
controls:29.59%
40
330
108
1139
36
190
114
1299
15
35
135
1454
—
9
32
139
1457
34
214
114
1256
57
371
72
883
Inpatient Hospital
21 [8717]
3.1e-01
8.5e-01
—
1.0e+50
9.5e-01
1.0e+00
6.8e-01
cases:34.46%
controls:27.84%
cases:20.67%
controls:10.01%
—
—
cases:11.33%
controls:0.00%
cases:4.05%
controls:1.61%
cases:20.95%
controls:8.57%
cases:36.43%
controls:22.57%
51
409
97
1060
31
149
119
1340
—
17
0
133
1489
6
24
142
1465
31
126
117
1344
47
283
82
971
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
7.1e-01
1.2e+00
—
—
—
6.3e-01
1.3e+00
cases:12.84%
controls:6.74%
cases:8.67%
controls:2.75%
—
—
—
—
—
—
cases:4.73%
controls:2.59%
cases:20.16%
controls:6.22%
19
99
129
1370
13
41
137
1448
—
—
—
7
38
141
1432
26
78
103
1176
Gas panel - Venous blood
24339-4 [3000991]
9.7e-01
—
—
—
—
2.3e+00
—
cases:5.41%
controls:2.11%
—
—
—
—
—
—
—
—
cases:4.05%
controls:0.41%
—
—
8
31
140
1438
—
—
—
—
6
6
142
1464
—
Laboratory Visit
OMOP4822461 [32036]
-1.7e-02
9.5e-02
7.1e-01
2.3e+00
8.1e-01
9.9e-02
2.7e-01
cases:33.11%
controls:33.49%
cases:30.67%
controls:28.68%
cases:16.00%
controls:8.60%
cases:4.00%
controls:0.40%
cases:15.54%
controls:7.59%
cases:33.11%
controls:30.95%
cases:52.71%
controls:45.85%
49
492
99
977
46
427
104
1062
24
128
126
1361
6
6
144
1483
23
113
125
1376
49
455
99
1015
68
575
61
679
Examination of eyes and vision
Z01.0 [45566391]
5.5e-01
2.2e+00
—
—
—
-1.0e+50
5.7e-02
cases:3.38%
controls:1.97%
cases:4.67%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:3.88%
controls:3.67%
5
29
143
1440
7
8
143
1481
—
—
—
0
7
148
1463
5
46
124
1208
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
2.8e-01
1.7e-01
—
—
2.2e+00
6.3e-01
2.0e-01
cases:12.16%
controls:9.46%
cases:4.67%
controls:3.96%
—
—
—
—
cases:4.05%
controls:0.47%
cases:7.43%
controls:4.08%
cases:14.73%
controls:12.36%
18
139
130
1330
7
59
143
1430
—
—
6
7
142
1482
11
60
137
1410
19
155
110
1099
Severe psychotic and other severe mental disorders
112 [2001600112]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.65%
controls:0.56%
—
—
—
—
—
—
6
7
123
1247
Neuropsychological investigation
XA800 [2001300412]
2.1e+00
—
—
—
—
—
—
cases:6.08%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
9
11
139
1458
—
—
—
—
—
—
Office Visit
OMOP4822458 [581477]
-3.3e-01
3.2e-01
—
—
—
1.3e+00
8.6e-01
cases:6.76%
controls:9.19%
cases:4.67%
controls:3.43%
—
—
—
—
—
—
cases:10.14%
controls:3.13%
cases:20.93%
controls:10.05%
10
135
138
1334
7
51
143
1438
—
—
—
15
46
133
1424
27
126
102
1128
carbamazepine; oral, rectal
N03AF01 [21604417]
2.1e+00
—
—
—
—
—
—
cases:4.73%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
141
1460
—
—
—
—
—
—
topiramate; oral
N03AX11 [21604433]
2.0e+00
—
—
—
—
1.0e+50
2.1e+00
cases:3.38%
controls:0.48%
—
—
—
—
—
—
—
—
cases:3.38%
controls:0.00%
cases:5.43%
controls:0.72%
5
7
143
1462
—
—
—
—
5
0
143
1470
7
9
122
1245
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2.0e+00
—
—
—
—
—
—
cases:7.43%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
11
15
137
1454
—
—
—
—
—
—
pH of Arterial blood
2744-1 [3019977]
2.0e+00
—
—
—
—
—
—
cases:7.43%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
11
15
137
1454
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2.0e+00
—
—
—
—
—
—
cases:7.43%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
11
15
137
1454
—
—
—
—
—
—
Supine thorax X-ray examination
GD1QA [2001303648]
2.0e+00
—
—
—
—
—
—
cases:4.05%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
142
1461
—
—
—
—
—
—
Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]
-1.0e+50
-1.0e+50
—
—
—
—
2.0e+00
cases:0.00%
controls:1.23%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:4.65%
controls:0.64%
0
18
148
1451
0
8
150
1481
—
—
—
—
6
8
123
1246
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
2.0e+00
—
—
—
—
—
—
cases:5.41%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
8
11
140
1458
—
—
—
—
—
—
lamotrigine; oral
N03AX09 [21604431]
2.0e+00
—
—
—
—
1.9e+00
1.6e+00
cases:8.11%
controls:1.23%
—
—
—
—
—
—
—
—
cases:3.38%
controls:0.54%
cases:3.88%
controls:0.80%
12
18
136
1451
—
—
—
—
5
8
143
1462
5
10
124
1244
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.9e+00
—
—
—
—
—
—
cases:6.76%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
10
15
138
1454
—
—
—
—
—
—
pregabalin; oral
N02BF02 [955152]
6.5e-01
—
—
—
—
1.9e+00
1.2e+00
cases:4.73%
controls:2.52%
—
—
—
—
—
—
—
—
cases:6.08%
controls:0.95%
cases:9.30%
controls:2.95%
7
37
141
1432
—
—
—
—
9
14
139
1456
12
37
117
1217
More than one and less than three hours
ZXE10 [2001311401]
6.7e-01
—
—
—
—
1.9e+00
8.9e-01
cases:8.78%
controls:4.70%
—
—
—
—
—
—
—
—
cases:4.73%
controls:0.75%
cases:6.20%
controls:2.63%
13
69
135
1400
—
—
—
—
7
11
141
1459
8
33
121
1221
Other and unspecified convulsions
R56.8 [45602033]
1.9e+00
—
—
—
—
—
—
cases:4.73%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
141
1458
—
—
—
—
—
—
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.9e+00
—
—
—
—
—
—
cases:4.73%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
141
1458
—
—
—
—
—
—
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.30%
controls:1.59%
—
—
—
—
—
—
12
20
117
1234
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
1.8e+00
—
—
—
—
—
—
cases:4.73%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
7
12
141
1457
—
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.0e-01
6.4e-01
1.5e+00
—
1.0e+00
3.5e-01
5.9e-01
cases:26.35%
controls:22.74%
cases:22.00%
controls:12.89%
cases:10.67%
controls:2.48%
—
—
cases:6.08%
controls:2.22%
cases:19.59%
controls:14.63%
cases:43.41%
controls:29.82%
39
334
109
1135
33
192
117
1297
16
37
134
1452
—
9
33
139
1456
29
215
119
1255
56
374
73
880
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.7e-01
5.5e-01
1.5e+00
—
7.9e-01
4.5e-01
5.9e-01
cases:20.27%
controls:14.98%
cases:17.33%
controls:10.81%
cases:8.67%
controls:2.15%
—
—
cases:4.05%
controls:1.88%
cases:17.57%
controls:11.97%
cases:31.78%
controls:20.49%
30
220
118
1249
26
161
124
1328
13
32
137
1457
—
6
28
142
1461
26
176
122
1294
41
257
88
997
Physiotherapy
R4110 [2001310233]
1.4e+00
—
—
—
—
1.6e+00
6.6e-01
cases:11.49%
controls:3.06%
—
—
—
—
—
—
—
—
cases:4.73%
controls:0.95%
cases:5.43%
controls:2.87%
17
45
131
1424
—
—
—
—
7
14
141
1456
7
36
122
1218
Otolaryngology
4 [38004449]
4.4e-01
7.6e-01
—
—
1.9e+00
1.3e+00
5.9e-01
cases:14.86%
controls:10.14%
cases:7.33%
controls:3.56%
—
—
—
—
cases:3.38%
controls:0.54%
cases:10.81%
controls:3.13%
cases:16.28%
controls:9.73%
22
149
126
1320
11
53
139
1436
—
—
5
8
143
1481
16
46
132
1424
21
122
108
1132
Laceration/cut
S18 [2002000983]
1.3e+00
1.0e+00
—
—
—
1.2e+00
8.7e-01
cases:11.49%
controls:3.40%
cases:3.33%
controls:1.21%
—
—
—
—
—
—
cases:5.41%
controls:1.63%
cases:13.18%
controls:5.98%
17
50
131
1419
5
18
145
1471
—
—
—
8
24
140
1446
17
75
112
1179
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.0e-01
4.1e-01
1.3e+00
—
7.8e-01
2.1e-01
5.2e-01
cases:27.70%
controls:23.96%
cases:22.00%
controls:15.78%
cases:10.67%
controls:3.22%
—
—
cases:6.08%
controls:2.89%
cases:20.95%
controls:17.62%
cases:45.74%
controls:33.33%
41
352
107
1117
33
235
117
1254
16
48
134
1441
—
9
43
139
1446
31
259
117
1211
59
418
70
836
pH of Serum or Plasma
2753-2 [3018418]
8.6e-01
—
—
—
—
—
1.2e+00
cases:9.46%
controls:4.22%
—
—
—
—
—
—
—
—
—
—
cases:11.63%
controls:3.75%
14
62
134
1407
—
—
—
—
—
15
47
114
1207
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.2e+00
—
—
—
—
—
9.6e-01
cases:10.81%
controls:3.68%
—
—
—
—
—
—
—
—
—
—
cases:10.85%
controls:4.47%
16
54
132
1415
—
—
—
—
—
14
56
115
1198
Short blood count panel - Blood
55429-5 [40758558]
5.2e-01
4.2e-01
—
—
—
8.3e-01
1.1e+00
cases:7.43%
controls:4.56%
cases:3.33%
controls:2.22%
—
—
—
—
—
—
cases:4.73%
controls:2.11%
cases:11.63%
controls:4.07%
11
67
137
1402
5
33
145
1456
—
—
—
7
31
141
1439
15
51
114
1203
No disease
A97 [2002000230]
7.8e-01
—
—
—
—
—
1.1e+00
cases:4.05%
controls:1.91%
—
—
—
—
—
—
—
—
—
—
cases:10.08%
controls:3.51%
6
28
142
1441
—
—
—
—
—
13
44
116
1210
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
7.1e-01
9.0e-01
—
—
—
1.5e-01
1.1e+00
cases:13.51%
controls:7.15%
cases:8.00%
controls:3.43%
—
—
—
—
—
—
cases:3.38%
controls:2.93%
cases:20.16%
controls:7.58%
20
105
128
1364
12
51
138
1438
—
—
—
5
43
143
1427
26
95
103
1159
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
-6.6e-02
—
—
—
—
—
1.1e+00
cases:4.73%
controls:5.04%
—
—
—
—
—
—
—
—
—
—
cases:13.18%
controls:4.86%
7
74
141
1395
—
—
—
—
—
17
61
112
1193
Emergency Room Visit
ER [9203]
5.0e-01
1.0e+00
—
1.0e+50
1.5e+00
7.4e-01
3.7e-01
cases:40.54%
controls:29.27%
cases:24.00%
controls:10.01%
—
—
cases:4.67%
controls:0.00%
cases:4.73%
controls:1.14%
cases:18.24%
controls:9.59%
cases:35.66%
controls:27.75%
60
430
88
1039
36
149
114
1340
—
7
0
143
1489
7
17
141
1472
27
141
121
1329
46
348
83
906
Emergency Medicine
93 [38004510]
4.5e-01
1.0e+00
—
—
—
6.7e-01
3.0e-01
cases:16.22%
controls:11.03%
cases:14.00%
controls:5.57%
—
—
—
—
—
—
cases:12.16%
controls:6.60%
cases:20.16%
controls:15.71%
24
162
124
1307
21
83
129
1406
—
—
—
18
97
130
1373
26
197
103
1057
Pain in limb
M79.6 [45587063]
3.7e-01
—
—
—
-1.0e+50
—
1.0e+00
cases:6.08%
controls:4.29%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
cases:12.40%
controls:4.94%
9
63
139
1406
—
—
—
0
6
148
1483
—
16
62
113
1192
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
-5.8e-01
3.1e-01
—
—
—
4.3e-01
9.4e-01
cases:4.05%
controls:7.01%
cases:4.00%
controls:2.96%
—
—
—
—
—
—
cases:4.73%
controls:3.13%
cases:14.73%
controls:6.30%
6
103
142
1366
6
44
144
1445
—
—
—
7
46
141
1424
19
79
110
1175
Ophthalmology
18 [38004463]
6.5e-01
9.7e-01
—
—
—
9.3e-01
4.7e-01
cases:16.22%
controls:9.19%
cases:9.33%
controls:3.76%
—
—
—
—
—
—
cases:12.84%
controls:5.51%
cases:19.38%
controls:13.08%
24
135
124
1334
14
56
136
1433
—
—
—
19
81
129
1389
25
164
104
1090
One-surface restoration
SFA10 [2001310358]
2.2e-01
1.0e-01
-1.0e+50
—
—
3.3e-02
7.8e-01
cases:14.19%
controls:11.71%
cases:4.00%
controls:3.63%
cases:0.00%
controls:0.67%
—
—
—
—
cases:5.41%
controls:5.24%
cases:28.68%
controls:15.63%
21
172
127
1297
6
54
144
1435
0
10
150
1479
—
—
8
77
140
1393
37
196
92
1058
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
3.5e-01
2.1e-01
—
—
—
2.7e-01
7.7e-01
cases:14.86%
controls:10.96%
cases:6.00%
controls:4.90%
—
—
—
—
—
—
cases:7.43%
controls:5.78%
cases:28.68%
controls:15.71%
22
161
126
1308
9
73
141
1416
—
—
—
11
85
137
1385
37
197
92
1057
Acute lymphoblastic leukaemia [ALL]
C91.0 [45537873]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.81%
cases:0.00%
controls:0.40%
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.88%
cases:0.00%
controls:0.88%
0
11
148
1458
0
12
150
1477
0
6
150
1483
—
0
5
148
1484
0
13
148
1457
0
11
129
1243
Carbon dioxide [Partial pressure] in Blood
11557-6 [3013290]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
5
150
1484
—
—
—
—
—
Epilepsy
G40 [45595935]
—
1.0e+50
—
—
—
—
1.0e+50
—
—
cases:3.33%
controls:0.00%
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.00%
—
5
0
145
1489
—
—
—
—
5
0
124
1254
No procedures
SPAT1301 [2001700402]
-1.4e-01
—
-1.0e+50
—
—
1.2e+00
7.5e-01
cases:4.05%
controls:4.63%
—
—
cases:0.00%
controls:0.54%
—
—
—
—
cases:3.38%
controls:1.09%
cases:10.08%
controls:5.02%
6
68
142
1401
—
0
8
150
1481
—
—
5
16
143
1454
13
63
116
1191
gestodene and ethinylestradiol
G03AB06 [21602494]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
6
148
1463
—
—
—
—
—
0
5
129
1249
Benign neoplasm: Skin of trunk
D23.5 [45581294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Preventive oral health care, short
SCA01 [2001310302]
-6.6e-02
—
-1.0e+50
—
-1.0e+50
1.2e-01
2.4e-01
cases:7.43%
controls:7.90%
—
—
cases:0.00%
controls:0.40%
—
—
cases:0.00%
controls:0.40%
cases:3.38%
controls:2.99%
cases:11.63%
controls:9.41%
11
116
137
1353
—
0
6
150
1483
—
0
6
148
1483
5
44
143
1426
15
118
114
1136
Transient global amnesia
G45.4 [45566883]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
mometasone, combinations
R01AD59 [947911]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:1.12%
—
—
—
—
—
0
10
148
1460
0
14
129
1240
Other obstetric ultrasound examination
MA2XE [2001306838]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
148
1459
—
—
—
—
—
—
mupirocin; nasal
R01AX06 [21603201]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
0
5
150
1484
—
—
—
—
0
9
129
1245
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.97%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
29
148
1440
0
7
150
1482
—
—
—
—
—
Assessment of need for oral health care, extensive
SAD02 [2001310288]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
148
1459
—
—
—
—
—
—
Restricted oral and dental health check by dental hygienist or dental assistant
SAB01 [2001310279]
7.4e-01
—
—
—
—
—
—
cases:4.05%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
—
—
6
29
142
1440
—
—
—
—
—
—
Other specified local infections of skin and subcutaneous tissue
L08.8 [45601211]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
6
129
1248
sitagliptin; oral
A10BH01 [21600784]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
0
9
148
1460
0
5
150
1484
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
1.0e+00
—
—
—
—
—
5.3e-01
cases:6.76%
controls:2.59%
—
—
—
—
—
—
—
—
—
—
cases:6.98%
controls:4.23%
10
38
138
1431
—
—
—
—
—
9
53
120
1201
Monitoring the use of the aid
R5140 [2001310249]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.88%
—
—
—
—
—
—
5
11
124
1243
Basic examination of mouth
SAA02 [2001310275]
-3.7e-02
-7.8e-01
—
—
—
-5.5e-01
3.0e-01
cases:17.57%
controls:18.11%
cases:3.33%
controls:6.98%
—
—
—
—
—
—
cases:4.73%
controls:7.96%
cases:29.46%
controls:23.60%
26
266
122
1203
5
104
145
1385
—
—
—
7
117
141
1353
38
296
91
958
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
1.8e+00
—
—
—
—
—
—
cases:4.05%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
6
10
142
1459
—
—
—
—
—
—
Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight
60477-7 [40763531]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.56%
0
16
148
1453
—
—
—
—
0
5
148
1465
0
7
129
1247
pH of Venous blood
2746-6 [3012544]
6.7e-01
—
—
—
—
—
6.1e-01
cases:4.05%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:2.15%
6
31
142
1438
—
—
—
—
—
5
27
124
1227
Abdominal CT examination
JN3AD [2001305554]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
9
129
1245
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
7
150
1482
—
—
—
0
6
148
1464
—
Primary arthrosis of other joints
M19.0 [45601353]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:1.28%
—
—
—
—
—
0
6
148
1464
0
16
129
1238
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
drospirenone
G03AC10 [1588689]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
cases:0.00%
controls:0.40%
cases:0.00%
controls:0.61%
—
—
—
0
7
150
1482
—
—
0
6
148
1483
0
9
148
1461
—
Extensive body CT
JN4BD [2001310899]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
5
148
1465
—
Fracture of tooth, open
S02.51 [45755762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
0
12
129
1242
Laparoscopic salpingectomy
LBE01 [2001306505]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Angina pectoris, unspecified
I20.90 [2000502402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
Asthma
R96 [2002000961]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
148
1455
—
—
—
—
—
—
Postpartum check-up
SPAT1380 [2001700480]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.57%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
0
23
148
1446
0
7
150
1482
—
—
—
0
5
148
1465
—
Periodontal treatment, very brief
SDA01 [2001310326]
1.7e-01
—
—
—
—
1.0e+00
1.6e-01
cases:4.73%
controls:4.02%
—
—
—
—
—
—
—
—
cases:3.38%
controls:1.22%
cases:7.75%
controls:6.70%
7
59
141
1410
—
—
—
—
5
18
143
1452
10
84
119
1170
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
0
10
150
1479
—
—
—
—
—
Other oral or dental procedure, restricted
SXC02 [2001310583]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
Occupational therapy
R4120 [2001310234]
2.1e+00
—
—
—
—
—
—
cases:3.38%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
5
6
143
1463
—
—
—
—
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
2.7e-01
-2.4e-01
—
—
—
8.1e-01
6.7e-01
cases:11.49%
controls:9.05%
cases:4.00%
controls:5.04%
—
—
—
—
—
—
cases:9.46%
controls:4.42%
cases:18.60%
controls:10.45%
17
133
131
1336
6
75
144
1414
—
—
—
14
65
134
1405
24
131
105
1123
Exhaustion and fatigue pregnancy-related
O26.82 [2000503207]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
ticagrelor; oral
B01AC24 [40252640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Orthodontics
143 [44777673]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
scopolamine
A04AD01 [21600499]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.29%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
0
19
148
1450
0
5
150
1484
—
—
—
0
6
148
1464
—
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
2.5e-01
-2.3e-02
—
—
—
8.0e-01
7.2e-01
cases:10.81%
controls:8.65%
cases:4.67%
controls:4.77%
—
—
—
—
—
—
cases:8.11%
controls:3.81%
cases:17.05%
controls:9.09%
16
127
132
1342
7
71
143
1418
—
—
—
12
56
136
1414
22
114
107
1140
Personal history of leukaemia
Z85.6 [45609980]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
0
5
148
1464
—
—
—
—
—
0
6
129
1248
methylphenidate; oral
N06BA04 [21604757]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.65%
controls:1.28%
—
—
—
—
—
—
6
16
123
1238
betamethasone
S03BA03 [21605203]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
—
0
13
150
1476
—
—
—
—
—
desonide
D07AB08 [21602112]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
0
11
150
1478
—
—
—
—
—
Allergic urticaria
L50.0 [45581945]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
5
148
1464
—
—
—
—
—
0
8
129
1246
Allergy, unspecified
T78.4 [45580373]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
5
150
1484
—
—
—
—
—
Melaena
K92.1 [45533624]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Striking against or struck by other object(s)
W22 [45756260]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.88%
—
—
—
—
—
—
5
11
124
1243
Positioning and fixed attachment of brackets
SJC02 [2001310429]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
Other function in accordance with speech therapy nomenclature
SPAT1297 [2001700398]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
pH of Capillary blood
2745-8 [3009343]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
—
0
13
150
1476
—
—
—
—
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
5.6e-02
2.0e-01
—
—
—
3.0e-01
4.3e-01
cases:27.03%
controls:25.94%
cases:10.00%
controls:8.33%
—
—
—
—
—
—
cases:9.46%
controls:7.21%
cases:30.23%
controls:21.93%
40
381
108
1088
15
124
135
1365
—
—
—
14
106
134
1364
39
275
90
979
Melanocytic naevi
D22 [45595739]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
5
148
1465
—
Need for immunization against influenza
Z25.1 [45581017]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
1.3e+00
—
—
—
—
—
1.1e+00
cases:4.73%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
cases:6.20%
controls:2.15%
7
20
141
1449
—
—
—
—
—
8
27
121
1227
Psychiatric treatment plan, permanent discontinuation
ICC04 [2001304105]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
148
1463
—
—
—
—
—
—
nystatin; oral
A07AA02 [21600604]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
0
7
150
1482
—
—
—
—
—
tamsulosin; oral
G04CA02 [21602669]
—
—
—
—
—
—
1.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:3.51%
—
—
—
—
—
—
5
44
124
1210
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
J07AH08 [21601303]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
6
129
1248
Atrial fibrillation and flutter
I48 [45596206]
—
—
—
—
—
—
5.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:2.23%
—
—
—
—
—
—
5
28
124
1226
Other ultrasound examination during pregnancy
SPAT1189 [2001700290]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
0
10
148
1459
—
—
—
—
—
0
6
129
1248
Preventive oral care by dental hygienist or dental assistant, restricted
SCF01 [2001310318]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
-1.5e-02
-3.2e-01
-1.0e+50
—
-1.0e+50
-4.9e-01
2.8e-02
cases:12.16%
controls:12.32%
cases:7.33%
controls:9.81%
cases:0.00%
controls:1.07%
—
—
cases:0.00%
controls:0.94%
cases:6.76%
controls:10.54%
cases:17.05%
controls:16.67%
18
181
130
1288
11
146
139
1343
0
16
150
1473
—
0
14
148
1475
10
155
138
1315
22
209
107
1045
nitrofurantoin; oral
J01XE01 [21603058]
7.9e-01
—
—
—
—
—
9.6e-01
cases:5.41%
controls:2.52%
—
—
—
—
—
—
—
—
—
—
cases:5.43%
controls:2.15%
8
37
140
1432
—
—
—
—
—
7
27
122
1227
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
-1.0e+50
-1.0e+50
—
—
—
—
8.1e-01
cases:0.00%
controls:1.23%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:3.88%
controls:1.75%
0
18
148
1451
0
7
150
1482
—
—
—
—
5
22
124
1232
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
0
6
150
1483
—
—
—
0
5
148
1465
—
Obstetrics / Gynecology
16 [38004461]
1.8e-01
-1.6e-01
—
—
—
2.0e-01
1.2e-01
cases:17.57%
controls:15.11%
cases:5.33%
controls:6.18%
—
—
—
—
—
—
cases:6.08%
controls:5.03%
cases:13.95%
controls:12.52%
26
222
122
1247
8
92
142
1397
—
—
—
9
74
139
1396
18
157
111
1097
Spondylosis, unspecified
M47.9 [45557887]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Pediatric Surgery
OMOP4822020 [45756819]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
38
148
1431
—
—
—
—
—
—
pravastatin; oral
C10AA03 [21601858]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.64%
—
—
—
—
—
0
6
148
1464
0
8
129
1246
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.4e-01
3.7e-01
9.8e-01
—
5.6e-01
1.6e-01
5.5e-01
cases:27.03%
controls:22.60%
cases:20.00%
controls:14.71%
cases:6.67%
controls:2.62%
—
—
cases:4.73%
controls:2.75%
cases:18.92%
controls:16.60%
cases:44.96%
controls:32.06%
40
332
108
1137
30
219
120
1270
10
39
140
1450
—
7
41
141
1448
28
244
120
1226
58
402
71
852
olanzapine; oral, parenteral
N05AH03 [21604543]
1.1e+00
1.4e+00
—
—
—
—
1.4e+00
cases:3.38%
controls:1.16%
cases:3.33%
controls:0.81%
—
—
—
—
—
—
—
—
cases:5.43%
controls:1.36%
5
17
143
1452
5
12
145
1477
—
—
—
—
7
17
122
1237
Home Visit
OMOP4822459 [581476]
3.3e-01
—
-1.0e+50
—
—
8.5e-01
9.3e-01
cases:5.41%
controls:3.95%
—
—
cases:0.00%
controls:0.47%
—
—
—
—
cases:4.05%
controls:1.77%
cases:10.08%
controls:4.23%
8
58
140
1411
—
0
7
150
1482
—
—
6
26
142
1444
13
53
116
1201
Knee X-ray examination without contrast
NG1AA [2001308049]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
13
129
1241
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.64%
—
—
—
—
—
0
6
148
1464
0
8
129
1246
Pain localized to upper abdomen
R10.1 [45568111]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
12
150
1477
—
—
—
0
6
148
1464
—
macrogol; oral
A06AD15 [21600575]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
0
11
150
1478
0
6
150
1483
—
—
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
-1.7e-01
—
—
—
—
—
5.4e-01
cases:4.73%
controls:5.58%
—
—
—
—
—
—
—
—
—
—
cases:10.85%
controls:6.62%
7
82
141
1387
—
—
—
—
—
14
83
115
1171
folic acid
V04CX02 [715877]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
148
1456
—
—
—
—
—
—
glycerol
A06AX01 [21600597]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
0
11
148
1458
0
6
150
1483
—
—
—
0
5
148
1465
—
Disturbance of activity and attention
F90.0 [45542870]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.43%
controls:1.12%
—
—
—
—
—
—
7
14
122
1240
Allergic rhinitis due to pollen
J30.10 [2000502594]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.36%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
20
148
1449
0
9
150
1480
—
—
—
—
—
Nausea and vomiting
R11 [45539317]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
0
10
150
1479
—
—
—
—
—
Internal derangement of knee, unspecified
M23.9 [45567507]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
6
148
1464
—
Spirometry study
18759-1 [3000492]
—
-1.0e+50
—
—
—
-1.0e+50
7.7e-01
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:3.88%
controls:1.83%
—
0
7
150
1482
—
—
—
0
6
148
1464
5
23
124
1231
chlorhexidine, combinations
D08AC52 [21602208]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.65%
controls:1.67%
—
—
—
—
—
—
6
21
123
1233
Pap smear
SPAT1193 [2001700294]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.59%
—
0
10
150
1479
—
—
—
—
0
20
129
1234
pH of Urine
2756-5 [3015736]
2.6e-01
—
-1.0e+50
—
—
—
1.8e-01
cases:7.43%
controls:5.85%
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:10.08%
controls:8.53%
11
86
137
1383
—
0
11
150
1478
—
—
—
13
107
116
1147
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.48%
—
—
—
—
—
0
5
148
1465
0
6
129
1248
diclofenac; ointment
M02AA15 [21604051]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
0
9
150
1480
—
—
—
0
8
148
1462
—
Other primary gonarthrosis
M17.1 [45596493]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
0
6
150
1483
—
—
—
0
9
148
1461
—
Emergency Room and Inpatient Visit
ERIP [262]
6.4e-01
—
—
—
—
—
—
cases:8.11%
controls:4.42%
—
—
—
—
—
—
—
—
—
—
—
—
12
65
136
1404
—
—
—
—
—
—
Type 1 diabetes mellitus, With ketoacidosis
E10.1 [45542735]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
9
148
1460
—
—
—
—
—
0
5
129
1249
oxycodone and naloxone; oral
N02AA55 [21604265]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
8
150
1481
—
—
—
—
—
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
148
1459
—
—
—
—
—
—
formoterol, glycopyrronium bromide and beclometasone
R03AL09 [1502099]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma
1825-9 [3026285]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
32166-1 [3008714]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.56%
0
16
148
1453
—
—
—
—
0
5
148
1465
0
7
129
1247
Achilles tendinitis
M76.6 [45596682]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
—
—
—
—
—
—
Cystitis/urinary infection other
U71 [2002001191]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
148
1457
—
—
—
—
—
—
Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay
63453-5 [40766183]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
6
129
1248
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
0
9
150
1480
—
—
—
0
11
148
1459
—
Senile nuclear cataract
H25.1 [45581628]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
0
9
148
1460
—
—
—
—
0
7
148
1463
—
Surface analgesia on skin or mucosa
WX105 [2001310765]
—
-1.0e+50
—
—
—
—
1.2e+00
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:3.88%
controls:1.20%
—
0
10
150
1479
—
—
—
—
5
15
124
1239
formoterol; inhalant
R03AC13 [21603267]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.56%
0
9
148
1460
0
7
150
1482
—
—
—
0
6
148
1464
0
7
129
1247
fluticasone, combinations
R01AD58 [43534837]
-7.5e-02
—
—
—
—
—
—
cases:4.05%
controls:4.36%
—
—
—
—
—
—
—
—
—
—
—
—
6
64
142
1405
—
—
—
—
—
—
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
150
1484
—
0
5
148
1484
—
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
3.1e-01
5.5e-01
—
—
—
1.0e+00
8.3e-01
cases:8.11%
controls:6.06%
cases:3.33%
controls:1.95%
—
—
—
—
—
—
cases:4.73%
controls:1.77%
cases:10.85%
controls:5.02%
12
89
136
1380
5
29
145
1460
—
—
—
7
26
141
1444
14
63
115
1191
Need for immunization against unspecified infectious disease
Z26.9 [45590712]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Sleep disorder, unspecified
G47.9 [45595948]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.43%
controls:2.63%
—
—
—
—
—
—
7
33
122
1221
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
7.7e-01
—
-1.0e+50
—
—
—
—
cases:4.73%
controls:2.25%
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
7
33
141
1436
—
0
5
150
1484
—
—
—
—
FEV1
20150-9 [3024653]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
5
148
1465
—
Other specified anxiety disorders
F41.8 [45595908]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
0
5
150
1484
—
—
—
—
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.3e-01
4.0e-02
—
—
—
7.3e-01
7.1e-01
cases:12.16%
controls:10.82%
cases:6.00%
controls:5.78%
—
—
—
—
—
—
cases:10.14%
controls:5.17%
cases:20.93%
controls:11.48%
18
159
130
1310
9
86
141
1403
—
—
—
15
76
133
1394
27
144
102
1110
Atherosclerosis of arteries of extremities
I70.2 [45538421]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
148
1457
—
—
—
—
—
—
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
—
-1.0e+50
—
—
—
-1.0e+50
1.1e+00
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:3.88%
controls:1.28%
—
0
18
150
1471
—
—
—
0
11
148
1459
5
16
124
1238
General medical examination
Z00.0 [45585791]
6.1e-01
—
—
—
—
—
5.6e-01
cases:4.05%
controls:2.25%
—
—
—
—
—
—
—
—
—
—
cases:4.65%
controls:2.71%
6
33
142
1436
—
—
—
—
—
6
34
123
1220
Arthritis, unspecified
M13.9 [45567463]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
0
7
150
1482
—
—
—
—
—
Contusion of hip
S70.0 [45574306]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
9
129
1245
insulin (human); parenteral
A10AD01 [21600729]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
0
12
148
1477
—
—
Outcome of delivery
Z37 [45581024]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.75%
—
—
—
—
—
—
—
—
—
—
—
0
26
150
1463
—
—
—
—
—
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.64%
—
—
—
—
—
—
5
8
124
1246
Acute stress reaction
P02 [2002000799]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
5
150
1484
—
—
—
—
—
Sprain and strain involving (anterior)(posterior) cruciate ligament of knee
S83.5 [45608523]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
9
148
1460
—
—
—
—
—
0
5
129
1249
Cervicobrachial syndrome
M53.1 [45567577]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
5
150
1484
—
—
—
—
—
Periodontitis pronounced
K05.31 [2000502729]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
0
12
148
1457
0
5
150
1484
—
—
—
—
—
valdecoxib; oral
M01AH03 [21603994]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
terbinafine; oral
D01BA02 [21601967]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
0
14
150
1475
—
—
0
5
148
1484
—
—
General and Unspecified, Clarification/discussion RFE/demand
A48 [2002000182]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
0
6
150
1483
—
—
—
—
0
10
129
1244
Cutaneous abscess, furuncle and carbuncle, unspecified
L02.9 [45591620]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
6
129
1248
Upper respiratory infection acute
R74 [2002000942]
2.1e-01
6.4e-01
-1.0e+50
—
—
—
5.1e-02
cases:7.43%
controls:6.13%
cases:4.00%
controls:2.15%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:8.53%
controls:8.13%
11
90
137
1379
6
32
144
1457
0
7
150
1482
—
—
—
11
102
118
1152
Pain in thoracic spine
M54.6 [45606247]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
6.7e-01
—
—
—
—
—
—
cases:4.05%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
6
31
142
1438
—
—
—
—
—
—
Therapeutic intervention or check-up related to orthodontic treatment
SJX21 [2001310455]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
0
12
148
1457
0
6
150
1483
—
—
—
—
—
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
—
—
—
—
—
—
CPAP therapy
WX723 [2001310826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
6
129
1248
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.96%
—
—
—
—
—
0
6
148
1464
0
12
129
1242
Trigger finger
M65.3 [45538828]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
8
129
1246
pivmecillinam; oral
J01CA08 [21602827]
2.6e-01
—
—
—
—
3.3e-01
1.2e-01
cases:10.14%
controls:7.96%
—
—
—
—
—
—
—
—
cases:3.38%
controls:2.45%
cases:7.75%
controls:6.94%
15
117
133
1352
—
—
—
—
5
36
143
1434
10
87
119
1167
Tooth X-ray additional picture
EB1CA [2001301909]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
0
7
150
1482
—
—
—
0
7
148
1463
—
Silver Birch IgE Ab [Units/volume] in Serum
15283-5 [3027300]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
6
129
1248
Other single spontaneous delivery
O80.8 [45534307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
148
1457
—
—
—
—
—
—
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.79%
cases:0.00%
controls:0.81%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
0
41
148
1428
0
12
150
1477
—
—
—
0
10
148
1460
—
calcium carbonate
A02AC01 [21600065]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
0
7
148
1462
0
5
150
1484
—
—
—
0
6
148
1464
—
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
5
148
1465
—
Calculus of gallbladder without cholecystitis
K80.2 [45552951]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
0
12
129
1242
Psychiatric treatment plan, standard
ICB01 [2001304098]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
0
7
148
1463
—
Bacteria identified in Blood by Culture
600-7 [3023368]
7.4e-01
—
—
—
—
1.2e+00
1.8e-01
cases:6.08%
controls:3.00%
—
—
—
—
—
—
—
—
cases:4.05%
controls:1.22%
cases:3.88%
controls:3.27%
9
44
139
1425
—
—
—
—
6
18
142
1452
5
41
124
1213
Decompression of lumbar nerve roots
ABC36 [2001300475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
medroxyprogesterone; oral, parenteral
G03DA02 [21602540]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.72%
—
—
—
—
—
0
5
148
1465
0
9
129
1245
dexrabeprazole
A02BC07 [45893509]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
148
1456
—
—
—
—
—
—
Benign neoplasm: Skin, unspecified
D23.9 [45557064]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Fetal Trisomy 21 risk [Likelihood] Based on maternal age
49090-4 [3049207]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.56%
0
16
148
1453
—
—
—
—
0
5
148
1465
0
7
129
1247
Prostate specific Ag panel - Serum or Plasma
53764-7 [3039443]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Nonorganic insomnia
F51.0 [45552492]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
10
148
1460
—
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
1.2e-01
-2.2e-01
—
—
—
-1.3e-01
3.0e-01
cases:19.59%
controls:17.84%
cases:7.33%
controls:9.00%
—
—
—
—
—
—
cases:10.14%
controls:11.36%
cases:34.88%
controls:28.47%
29
262
119
1207
11
134
139
1355
—
—
—
15
167
133
1303
45
357
84
897
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
9
150
1480
—
—
—
—
—
Ankle symptom/complaint
L16 [2002000640]
9.3e-01
—
—
—
—
-1.0e+50
—
cases:3.38%
controls:1.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
5
20
143
1449
—
—
—
—
0
5
148
1465
—
triamcinolone and antiinfectives
S02CA04 [21605176]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
Guidance for breast-feeding and breast care
SPAT1200 [2001700301]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
Respiratory infection other
R83 [2002000951]
1.2e-01
—
—
—
—
—
-1.8e-01
cases:5.41%
controls:4.83%
—
—
—
—
—
—
—
—
—
—
cases:4.65%
controls:5.50%
8
71
140
1398
—
—
—
—
—
6
69
123
1185
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
0
16
150
1473
—
—
—
—
—
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:1.04%
0
10
148
1459
0
7
150
1482
—
—
—
0
6
148
1464
0
13
129
1241
bisoprolol; oral
C07AB07 [21601689]
1.9e-01
4.4e-01
6.2e-01
—
—
4.2e-01
5.1e-01
cases:9.46%
controls:7.96%
cases:10.00%
controls:6.65%
cases:3.33%
controls:1.81%
—
—
—
—
cases:10.14%
controls:6.87%
cases:16.28%
controls:10.45%
14
117
134
1352
15
99
135
1390
5
27
145
1462
—
—
15
101
133
1369
21
131
108
1123
Hemolysis interference index of Serum or Plasma
46424-8 [3052851]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
148
1463
—
—
—
—
—
—
scopolamine; oral, parenteral
N05CM05 [21604666]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.29%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
0
19
148
1450
0
5
150
1484
—
—
—
0
6
148
1464
—
Sequelae of cerebral infarction
I69.3 [45533476]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
7
129
1247
mometasone; nasal
R01AD09 [21605051]
-2.7e-01
—
-1.0e+50
—
-1.0e+50
5.7e-02
-4.4e-01
cases:6.76%
controls:8.65%
—
—
cases:0.00%
controls:0.54%
—
—
cases:0.00%
controls:0.60%
cases:3.38%
controls:3.20%
cases:6.20%
controls:9.33%
10
127
138
1342
—
0
8
150
1481
—
0
9
148
1480
5
47
143
1423
8
117
121
1137
Other diagnostic examination of periferal vessel
XPX99 [2001309755]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
—
—
—
—
—
—
insulin lispro; parenteral
A10AC04 [21600726]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
cases:0.00%
controls:2.59%
cases:0.00%
controls:2.55%
cases:0.00%
controls:0.67%
—
—
cases:0.00%
controls:0.54%
—
—
—
—
0
38
148
1431
0
38
150
1451
0
10
150
1479
—
0
8
148
1481
—
—
Benign paroxysmal vertigo
H81.1 [45572061]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
6
148
1463
—
—
—
—
—
0
5
129
1249
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.23%
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:1.83%
0
18
148
1451
0
11
150
1478
—
—
—
0
12
148
1458
0
23
129
1231
Another acute gingivitis
K05.08 [2000502715]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Spontaneous abortion, Complete or unspecified, without complication
O03.9 [45563040]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
Heartburn
R12 [45539318]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
148
1460
—
—
—
—
—
—
Fall on same level involving ice and snow
W00 [45756242]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
6
150
1483
—
—
—
—
—
Depressive disorder
P76 [2002000870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
10
129
1244
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
O99.3 [45606675]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
Examination for recruitment to armed forces
Z02.3 [45576125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
—
—
—
—
—
—
Erosion of teeth occupational
K03.29 [2000502681]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
triamcinolone; nasal
R01AD11 [21605052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
Abnormal uterine and vaginal bleeding, unspecified
N93.9 [45592158]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
olopatadine
R01AC08 [21605040]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:1.12%
—
—
—
—
—
0
10
148
1460
0
14
129
1240
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
2.1e-01
5.9e-01
-1.0e+50
—
-1.0e+50
—
-2.0e-01
cases:16.89%
controls:14.09%
cases:6.00%
controls:3.43%
cases:0.00%
controls:0.54%
—
—
cases:0.00%
controls:0.34%
—
—
cases:10.85%
controls:13.00%
25
207
123
1262
9
51
141
1438
0
8
150
1481
—
0
5
148
1484
—
14
163
115
1091
Gastro-oesophageal reflux disease
K21 [45586708]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
148
1461
—
—
—
—
—
—
flucloxacillin; oral, parenteral
J01CF05 [21602857]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
6
150
1483
—
—
—
—
—
loperamide oxide; oral
A07DA05 [21600648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
148
1458
—
—
—
—
—
—
hydroxocobalamin
V03AB33 [21605256]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
0
7
150
1482
—
—
—
—
—
Preventive immunization/medic
-44 [2002000115]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.88%
0
9
148
1460
0
5
150
1484
—
—
—
0
5
148
1465
0
11
129
1243
Vascular Surgery
77 [38004496]
—
—
—
—
—
—
8.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:1.75%
—
—
—
—
—
—
5
22
124
1232
Teeth/gum disease
D82 [2002000380]
4.7e-01
4.6e-01
—
—
—
5.2e-01
3.1e-01
cases:8.11%
controls:5.24%
cases:4.00%
controls:2.55%
—
—
—
—
—
—
cases:4.73%
controls:2.86%
cases:9.30%
controls:7.02%
12
77
136
1392
6
38
144
1451
—
—
—
7
42
141
1428
12
88
117
1166
Paediatric Clinical Immunology and Allergy
255 [44777768]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
12
148
1457
0
8
150
1481
—
—
—
—
0
9
129
1245
fusidic acid
S01AA13 [21603564]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
6
148
1464
—
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
8.1e-02
—
-1.0e+50
—
-1.0e+50
—
9.5e-02
cases:6.76%
controls:6.26%
—
—
cases:0.00%
controls:0.40%
—
—
cases:0.00%
controls:0.40%
—
—
cases:7.75%
controls:7.10%
10
92
138
1377
—
0
6
150
1483
—
0
6
148
1483
—
10
89
119
1165
Extraction of root of tooth
EBA30 [2001301929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
148
1463
—
—
—
—
—
—
aciclovir; oral, parenteral
J05AB01 [21603131]
4.5e-01
—
—
—
—
—
—
cases:3.38%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
—
—
5
32
143
1437
—
—
—
—
—
—
Medial epicondylitis
M77.0 [45557989]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
313 [2001600274]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
148
1464
—
—
—
—
—
—
First trimester maternal screen panel - Serum or Plasma
48798-3 [3050129]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
13
148
1456
—
—
—
—
—
0
5
129
1249
prednisone
A07EA03 [21600655]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:1.44%
—
—
—
—
—
0
6
148
1464
0
18
129
1236
Very demanding periodontal treatment
SDA05 [2001310330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
6
129
1248
insulin glargine; parenteral
A10AE04 [21600739]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:3.00%
cases:0.00%
controls:2.96%
cases:0.00%
controls:0.47%
—
—
cases:0.00%
controls:0.74%
cases:0.00%
controls:2.86%
—
—
0
44
148
1425
0
44
150
1445
0
7
150
1482
—
0
11
148
1478
0
42
148
1428
—
Monitoring of normal pregnancy
SPAT1196 [2001700297]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
148
1460
—
—
—
—
—
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
1.9e-01
—
-1.0e+50
—
-1.0e+50
2.0e-01
5.1e-01
cases:8.11%
controls:6.81%
—
—
cases:0.00%
controls:0.74%
—
—
cases:0.00%
controls:0.40%
cases:3.38%
controls:2.79%
cases:13.18%
controls:8.37%
12
100
136
1369
—
0
11
150
1478
—
0
6
148
1483
5
41
143
1429
17
105
112
1149
Supervision of other high-risk pregnancies
Z35.8 [45552076]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
0
17
148
1452
—
—
—
—
—
0
6
129
1248
calcium carbonate; oral
A12AA04 [21600863]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
0
7
148
1462
0
5
150
1484
—
—
—
0
6
148
1464
—
Sprain/strain of ankle
L77 [2002000696]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
5
150
1484
—
—
—
—
—
Hordeolum
H00.00 [2000502235]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
8
129
1246
Supervision of normal first pregnancy
Z34.0 [45595500]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:1.04%
—
—
—
—
—
0
5
148
1465
0
13
129
1241
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.02%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
0
15
148
1454
0
5
150
1484
—
—
—
0
7
148
1463
—
Chronic rhinitis
J31.0 [45572165]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
0
8
148
1461
—
—
—
—
—
0
13
129
1241
Gas panel - Arterial blood
24336-0 [3019060]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
0
7
148
1463
—
C reactive protein [Mass/volume] in Capillary blood
48421-2 [3051387]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
0
5
150
1484
—
—
—
—
—
azathioprine; oral, parenteral
L04AX01 [21603927]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
0
10
148
1459
0
5
150
1484
—
—
—
0
5
148
1465
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
8.5e-02
1.6e-01
1.2e+00
—
1.4e+00
1.1e-01
5.2e-01
cases:20.27%
controls:18.92%
cases:12.00%
controls:10.41%
cases:4.00%
controls:1.28%
—
—
cases:4.73%
controls:1.21%
cases:12.84%
controls:11.70%
cases:35.66%
controls:24.80%
30
278
118
1191
18
155
132
1334
6
19
144
1470
—
7
18
141
1471
19
172
129
1298
46
311
83
943
Gas panel - Capillary blood
24337-8 [3022313]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
11
150
1478
—
—
—
0
6
148
1464
—
salmeterol and fluticasone
R03AK06 [21603280]
—
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.81%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:2.31%
—
0
12
150
1477
0
6
150
1483
—
—
—
0
29
129
1225
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:1.20%
0
16
148
1453
—
—
—
—
0
7
148
1463
0
15
129
1239
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
—
8.8e-01
—
—
—
—
6.0e-01
—
—
cases:3.33%
controls:1.41%
—
—
—
—
—
—
—
—
cases:9.30%
controls:5.34%
—
5
21
145
1468
—
—
—
—
12
67
117
1187
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
X69 [45585661]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
—
—
—
—
—
—
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.72%
0
6
148
1463
—
—
—
—
0
6
148
1464
0
9
129
1245
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
4.9e-01
—
—
—
—
—
4.0e-01
cases:6.08%
controls:3.81%
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:2.63%
9
56
139
1413
—
—
—
—
—
5
33
124
1221
Fetal chromosomal abnormality screening
472825005 [43020943]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.54%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
0
8
148
1461
0
5
150
1484
—
—
—
0
5
148
1465
—
Anomalies of dental arch relationship
K07.22 [2000502768]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
148
1462
—
—
—
—
—
—
Limited function/disability NOS
A28 [2002000162]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.43%
controls:1.36%
—
—
—
—
—
—
7
17
122
1237
Pediatric Gastroenterology
OMOP4822029 [45756810]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
10
148
1459
—
—
—
—
—
0
9
129
1245
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
6.7e-01
—
—
—
—
—
—
cases:4.05%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
6
31
142
1438
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
5.8e-01
1.2e+00
—
—
—
-1.0e+50
8.3e-01
cases:4.05%
controls:2.31%
cases:3.33%
controls:1.01%
—
—
—
—
—
—
cases:0.00%
controls:1.29%
cases:8.53%
controls:3.91%
6
34
142
1435
5
15
145
1474
—
—
—
0
19
148
1451
11
49
118
1205
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
—
—
—
—
—
-1.0e+50
2.3e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
cases:3.88%
controls:3.11%
—
—
—
—
—
0
14
148
1456
5
39
124
1215
Other specified special examinations
Z01.8 [45581003]
6.3e-01
—
—
—
—
—
9.8e-02
cases:6.08%
controls:3.34%
—
—
—
—
—
—
—
—
—
—
cases:5.43%
controls:4.94%
9
49
139
1420
—
—
—
—
—
7
62
122
1192
Organisation of medication
SPAT1251 [2001700352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
5
129
1249
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
3.0e-01
3.0e-01
9.8e-01
—
—
1.3e-01
4.5e-01
cases:20.95%
controls:16.47%
cases:10.67%
controls:8.13%
cases:3.33%
controls:1.28%
—
—
—
—
cases:11.49%
controls:10.20%
cases:33.33%
controls:24.16%
31
242
117
1227
16
121
134
1368
5
19
145
1470
—
—
17
150
131
1320
43
303
86
951

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
12
5
25.42
9.02
2.7
3.0
26.55
16.04
umol/l
—
12
5
97
598
2.24
7.05
5.6
6.9
37.13
36.99
g/l
0.08
92
576
114
770
2.16
6.37
13.2
11.1
1.22
1.22
mmol/l
0.06
105
696
9
7
13.39
5.64
4.0
3.3
21.33
22.56
umol/l
—
9
7
47
237
2.30
5.34
6.9
11.3
1.26
0.99
mmol/l
0.31
42
188
39
184
2.40
5.14
8.1
13.7
104.33
104.54
mmol/l
0.06
39
184
31
131
2.62
5.13
8.9
18.2
7.40
7.42
ph
0.91
17
69
31
132
2.60
5.06
8.8
17.9
14.94
13.38
kpa
0.68
31
127
31
132
2.60
5.06
8.9
17.9
5.43
5.21
kpa
0.41
31
126
28
117
2.63
4.74
3.2
5.3
58.29
72.22
e9/l
1.59
16
85
46
241
2.19
4.73
7.3
11.3
7.36
7.38
ph
0.74
36
151
80
514
1.94
4.73
1.7
1.8
99.94
95.53
pmol/l
0.32
45
274
22
82
2.90
4.60
10.3
19.9
94.66
93.96
%
0.18
22
82
28
121
2.53
4.43
1.3
1.5
1211.36
1107.50
nmol/l
0.26
20
97
43
226
2.16
4.37
9.5
14.3
—
—
—
0
0
181
1578
3.05
4.25
23.9
15.3
138.79
139.62
mmol/l
2.79
176
1548
17
57
3.17
4.24
1.4
4.4
380.12
445.82
mg/l
0.29
17
57
17
57
3.17
4.24
1.5
4.7
2.45
17.02
e6/l
0.61
11
41
16
52
3.26
4.19
1.5
5.1
—
—
—
0
0
131
1023
1.85
3.94
9.6
11.6
3.70
3.71
e9/l
0.02
115
867
180
1581
2.80
3.84
22.4
15.3
3.96
3.95
mmol/l
0.28
174
1544
7
8
9.02
3.80
2.1
5.1
—
—
—
0
0
73
484
1.81
3.74
2.4
3.2
2.37
2.38
mmol/l
0.32
66
448
63
404
1.83
3.58
5.2
3.8
7.39
7.39
ph
0.29
45
273
16
58
2.92
3.51
8.8
7.6
36.93
36.99
°c
0.49
16
58
121
944
1.74
3.43
8.5
8.2
0.57
0.56
e9/l
0.18
105
802
121
946
1.74
3.38
8.5
8.2
0.04
0.04
e9/l
0.31
105
802
123
968
1.73
3.34
8.3
8.2
2.19
2.12
e9/l
0.27
106
848
6
7
8.79
3.28
1.3
1.1
—
—
—
0
0
55
350
1.80
3.16
4.4
4.4
—
—
—
0
0
80
570
1.68
3.07
5.5
7.4
—
—
—
0
0
123
986
1.67
2.95
8.7
8.7
0.17
0.20
e9/l
1.32
108
850
10
27
3.85
2.92
1.5
6.3
—
—
—
0
0
38
223
1.87
2.81
2.1
2.6
2.41
2.44
mmol/l
0.60
32
198
109
856
1.62
2.77
11.9
11.5
0.00
0.00
e9/l
0.50
87
666
5
6
8.51
2.76
2.2
1.2
100.20
86.17
umol/l
—
5
6
25
127
2.11
2.75
2.0
1.9
0.00
0.00
estimate
—
5
27
36
209
1.89
2.75
2.4
2.5
401.29
342.03
nmol/l
0.96
31
200
70
494
1.65
2.73
2.7
2.7
—
—
—
0
0
35
204
1.87
2.64
8.3
10.5
23.68
23.44
mmol/l
0.30
35
204
132
1097
1.63
2.57
8.4
7.3
96.75
95.42
u/l
0.07
126
1040
30
169
1.92
2.50
3.4
3.9
0.21
0.21
g/l
0.03
30
160
23
408
0.51
2.48
2.0
1.9
—
—
—
0
0
11
39
2.93
2.38
1.5
5.9
—
—
—
0
0
23
120
2.04
2.37
2.3
1.9
13.90
16.78
iu/l
0.18
15
90
38
235
1.77
2.37
20.1
16.3
23.61
24.71
mmol/l
1.78
38
235
17
81
2.20
2.20
2.4
13.3
0.79
0.60
%
1.58
17
81
6
14
4.38
2.16
2.2
1.3
—
—
—
0
0
20
104
2.03
2.09
2.4
2.0
7.35
7.59
u/l
0.04
12
72
6
15
4.09
2.05
1.0
1.0
275.00
330.80
mg/l
—
6
15
33
206
1.72
1.99
2.2
1.7
—
—
—
0
0
60
439
1.53
1.92
5.4
3.4
0.00
0.01
estimate
0.50
18
157
32
202
1.70
1.86
1.5
1.5
545.85
66102138.72
pmol/l
0.50
26
177
5
12
4.25
1.83
2.2
2.1
12.80
10.58
mmol/l
—
5
12
7
23
3.12
1.81
5.0
3.2
16.60
16.94
%
—
7
23
20
110
1.91
1.81
5.4
6.3
0.00
0.21
%
—
10
24
20
110
1.91
1.81
5.3
5.8
0.40
0.57
%
—
10
28
5
13
3.92
1.72
1.2
1.5
1.72
1.75
mmol/l
—
5
13
20
112
1.88
1.72
1.2
1.5
—
—
—
0
0
6
19
3.22
1.67
1.5
4.1
0.33
0.63
index
—
6
19
21
121
1.82
1.66
5.3
5.9
0.55
0.71
%
0.25
11
35
32
209
1.64
1.65
3.5
3.0
2.50
2.45
g/l
0.16
32
193
182
1707
1.99
1.63
16.2
10.2
—
—
—
0
0
145
1291
1.48
1.59
4.3
4.1
14.38
14.47
pmol/l
0.17
137
1198
10
44
2.34
1.58
1.2
2.5
—
—
—
0
0
29
187
1.65
1.57
4.1
3.2
20.24
22.18
%
0.33
29
180
80
643
1.41
1.54
9.3
8.6
—
—
—
0
0
5
15
3.39
1.53
2.6
4.1
31.40
31.60
pg
—
5
15
7
28
2.55
1.46
9.1
5.3
—
—
—
0
0
5
16
3.18
1.44
11.4
2.5
23.00
31.81
mmol/l
—
5
16
17
96
1.84
1.44
1.1
1.1
—
—
—
0
0
54
409
1.44
1.43
4.6
2.6
—
—
—
0
0
69
551
1.39
1.35
14.4
7.9
1.16
1.12
inr
0.24
57
447
29
195
1.57
1.34
14.4
8.8
—
—
—
0
0
178
1674
1.73
1.34
18.4
13.0
26.94
23.47
mg/l
0.62
150
1284
46
344
1.44
1.30
5.2
3.0
7.10
6.60
e6/l
0.12
46
309
19
117
1.69
1.23
5.6
6.3
0.33
0.08
%
—
9
26
160
1483
1.44
1.14
4.9
4.9
1.78
1.89
mu/l
0.69
148
1397
123
1101
1.32
1.05
3.9
3.9
44.62
37.53
u/l
0.48
116
1070
7
37
1.92
0.95
7.1
6.7
—
—
—
0
0
97
850
1.28
0.94
5.1
3.5
0.00
0.00
estimate
-0.00
19
159
81
694
1.29
0.93
3.8
3.3
6.38
6.20
ph
0.71
43
374
44
346
1.35
0.93
3.5
2.8
—
—
—
0
0
64
532
1.30
0.93
6.2
3.8
35.24
30.98
e6/l
0.09
51
403
5
104
0.47
0.92
2.6
1.8
—
—
—
0
0
49
393
1.33
0.91
3.7
3.0
1.01
1.02
kg/l
1.24
33
245
38
293
1.37
0.91
4.9
3.5
0.74
1.95
e6/l
1.21
14
148
6
29
2.10
0.90
1.2
1.1
—
—
—
0
0
96
844
1.27
0.89
5.3
3.5
0.00
0.00
estimate
-0.00
19
163
6
30
2.03
0.87
1.7
1.1
224.83
316.96
mu/l
—
6
25
51
414
1.31
0.87
4.3
3.6
—
—
—
0
0
10
57
1.80
0.85
2.2
1.7
30.60
17.79
ng/l
—
10
57
31
234
1.39
0.84
1.3
1.5
435.56
421.28
titre
—
9
47
0
28
0.00
0.76
0.0
1.5
—
—
—
0
0
96
857
1.24
0.74
5.3
3.5
0.00
0.00
estimate
-0.00
20
157
9
56
1.64
0.73
12.1
12.8
—
—
—
0
0
47
388
1.28
0.71
8.5
5.4
—
—
—
0
0
79
694
1.23
0.70
3.0
3.2
—
—
estimate
—
0
0
5
27
1.87
0.69
4.0
4.0
17.00
8.59
%
—
5
27
5
27
1.87
0.69
2.0
2.1
—
—
—
0
0
71
618
1.23
0.69
5.0
3.1
0.00
0.00
estimate
-0.00
18
139
62
532
1.24
0.68
2.0
1.9
—
—
—
0
0
53
447
1.25
0.68
4.9
2.7
18.04
40.10
ng/l
1.02
39
243
5
29
1.74
0.64
17.0
5.4
9.96
8.24
pmol/l
—
5
29
71
623
1.22
0.63
7.7
4.7
117.03
33.62
e6/l
0.86
51
421
55
474
1.22
0.58
6.4
3.8
0.27
0.36
e6/l
0.28
43
342
38
314
1.26
0.58
2.8
2.5
189.71
71.45
ug/g
0.94
28
250
6
36
1.69
0.57
1.2
2.0
—
—
—
0
0
6
36
1.69
0.57
1.2
2.0
—
—
—
0
0
6
36
1.69
0.57
1.2
2.0
—
—
—
0
0
6
36
1.69
0.57
1.2
2.0
—
—
—
0
0
10
147
0.66
0.56
2.0
1.8
—
—
—
0
0
6
38
1.60
0.55
1.0
1.1
—
—
—
0
0
144
1363
1.22
0.54
4.6
3.8
5.58
5.67
mmol/l
0.55
134
1268
189
1853
1.65
0.53
29.3
19.9
133.66
135.95
g/l
1.35
189
1840
6
39
1.56
0.53
14.2
3.6
7.42
7.40
ph
—
6
39
33
393
0.81
0.49
1.5
1.8
—
—
—
0
0
16
120
1.36
0.48
8.0
3.4
—
—
—
0
0
25
204
1.26
0.43
2.8
2.3
—
—
—
0
0
5
31
1.63
0.43
1.0
1.2
—
—
—
0
0
8
58
1.40
0.42
1.1
1.4
—
100.00
—
0
8
5
33
1.53
0.41
2.0
2.2
—
—
—
0
0
13
171
0.74
0.41
1.2
1.2
—
—
—
0
0
8
59
1.37
0.41
1.1
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
210.81
—
0
16
61
548
1.16
0.41
1.4
1.6
—
—
—
0
0
5
36
1.40
0.38
4.4
3.4
43.86
37.53
%
—
5
36
9
68
1.34
0.38
2.0
1.9
—
—
—
0
0
9
70
1.30
0.37
2.9
1.5
—
—
—
0
0
12
90
1.36
0.36
1.2
1.2
—
—
—
0
0
6
45
1.34
0.34
4.5
16.0
66.82
67.33
%
—
6
45
6
88
0.67
0.33
1.3
1.1
—
—
—
0
0
64
586
1.14
0.33
1.3
1.6
1.13
1.93
u/ml
0.38
20
133
29
335
0.84
0.33
3.1
3.3
26.66
86.96
mg/l
1.67
19
226
15
184
0.80
0.30
1.6
1.5
—
—
—
0
0
56
610
0.89
0.29
2.6
2.6
—
—
—
0
0
36
319
1.16
0.29
2.3
3.6
0.78
1.37
mg/l
0.90
29
257
145
1403
1.13
0.28
4.9
4.6
2.75
2.75
mmol/l
0.01
139
1339
43
474
0.88
0.27
2.6
2.1
—
—
—
0
0
160
1559
1.15
0.26
22.4
17.0
334.79
334.52
g/l
0.13
160
1552
14
168
0.82
0.24
1.6
1.8
3.56
3.46
mmol/l
—
9
120
0
11
0.00
0.21
0.0
22.9
—
0.57
—
0
11
0
11
0.00
0.21
0.0
8.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
212.44
—
0
11
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
10
80
1.26
0.21
1.4
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
26
232
1.14
0.20
2.7
3.4
484.56
490.87
ng/l
0.01
18
149
6
51
1.18
0.19
1.2
15.3
63.48
67.96
%
—
6
51
31
281
1.12
0.19
1.2
1.3
20.59
25.17
iu/ml
—
10
71
5
69
0.72
0.17
1.0
1.0
1.62
1.51
g/l
—
5
69
142
1388
1.08
0.16
4.4
4.3
1.41
1.45
mmol/l
0.40
137
1320
49
460
1.09
0.16
5.0
2.7
0.00
0.01
estimate
0.50
17
134
28
259
1.09
0.12
1.7
1.5
—
—
—
0
0
16
144
1.12
0.11
1.1
1.2
—
—
—
0
0
24
259
0.92
0.10
1.3
1.3
6.94
6.93
u/ml
0.00
14
98
57
547
1.06
0.10
1.8
1.6
1.98
1.98
g/l
0.01
31
317
15
166
0.90
0.10
1.5
1.7
—
—
—
0
0
15
136
1.11
0.09
1.3
1.4
—
—
—
0
0
5
65
0.76
0.08
1.0
1.0
—
0.50
—
0
8
7
65
1.08
0.08
1.3
1.1
—
—
—
0
0
6
71
0.84
0.08
1.5
1.1
0.82
0.83
g/l
—
6
71
6
70
0.85
0.08
1.3
1.3
—
—
—
0
0
28
296
0.94
0.08
2.0
1.9
—
—
—
0
0
32
335
0.95
0.06
3.2
3.9
2.66
8.64
mg/mmol
2.04
20
219
21
223
0.93
0.06
1.1
1.2
—
—
—
0
0
60
615
0.96
0.05
1.8
2.0
1.23
1.41
mmol/l
1.21
55
551
127
1282
0.97
0.03
5.4
4.8
35.83
37.37
mmol/mol
1.74
122
1224
15
158
0.95
0.02
1.6
1.7
—
—
—
0
0
17
162
1.05
0.02
2.0
2.4
0.49
0.64
ug/l
0.99
11
84
17
162
1.05
0.02
1.5
1.7
—
—
—
0
0
20
192
1.05
0.02
1.6
1.8
—
—
—
0
0
132
1311
1.02
0.02
4.0
3.8
1.16
1.25
mmol/l
0.75
125
1248
17
164
1.04
0.00
1.5
1.7
—
—
—
0
0
15
149
1.01
0.00
1.1
1.6
—
—
—
0
0
17
165
1.03
0.00
1.5
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
105.50
—
0
6
0
6
0.00
0.00
0.0
5.3
—
49.42
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
27.43
—
0
7
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
7.7
—
8.62
—
0
8
0
8
0.00
-0.00
0.0
3.9
—
38.38
—
0
8
0
5
0.00
-0.00
0.0
2.6
—
29.00
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
2.66
—
0
7
7
76
0.92
-0.00
1.9
2.1
—
4.79
—
0
16
0
7
0.00
-0.00
0.0
1.1
—
2049.29
—
0
7
0
8
0.00
-0.00
0.0
1.1
—
0.49
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
-0.00
3.2
4.6
4.82
13.92
umol/l
—
5
42

Mortality – FinRegistry

↥

Association

Association between endpoint Q17_OTHER_CONGEN_MALFO_BRAIN and mortality.

Females

Parameter HR [95% CI] p-value
Q17_OTHER_CONGEN_MALFO_BRAIN 4.599 [3.29, 6.44] < 0.001
Birth year 0.992 [0.98, 1.0] 0.067

During the follow-up period (1.1.1998 — 31.12.2019), 86 out of 1102 females with Q17_OTHER_CONGEN_MALFO_BRAIN died.

Males

Parameter HR [95% CI] p-value
Q17_OTHER_CONGEN_MALFO_BRAIN 3.755 [2.72, 5.18] < 0.001
Birth year 0.989 [0.98, 1.0] 0.018

During the follow-up period (1.1.1998 — 31.12.2019), 103 out of 1405 males with Q17_OTHER_CONGEN_MALFO_BRAIN died.

Mortality risk

Mortality risk for people of age

years, who have Q17_OTHER_CONGEN_MALFO_BRAIN.

N-year risk Females Males
1 0.47% 0.765%
5 2.279% 4.579%
10 5.364% 10.956%
15 10.385% 19.83%
20 18.528% 32.143%

Relationships between endpoints

↥

Index endpoint: Q17_OTHER_CONGEN_MALFO_BRAIN – Other congenital malformations of brain

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data